Literature DB >> 15134780

Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling.

David A Fruman1.   

Abstract

Phosphoinositide 3-kinase (PI3K) activation is essential for lymphocyte proliferation driven by receptors for antigen, costimulatory ligands and cytokines. The lipid products of PI3K contribute to the assembly of membrane-associated signaling complexes by promoting recruitment of selected proteins from the cytoplasm. Many proteins possess domains that are able to bind selectively to PI3K products. Different 'PI3K effector' proteins are coupled to distinct biological responses, depending on cell type and on the receptor that is engaged. In B cells and T cells, Tec-family tyrosine kinases and Akt serine/threonine kinases are emerging as crucial mediators of proliferation and survival signals downstream of PI3K. Of particular interest is recent evidence that PI3K signaling controls increases in lymphocyte size and metabolic activity that accompany cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15134780     DOI: 10.1016/j.coi.2004.03.014

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  46 in total

1.  Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Authors:  Monika Edelbauer; Dipak Datta; Ingrid H C Vos; Aninda Basu; Maria P Stack; Marlies E J Reinders; Masayuki Sho; Katiana Calzadilla; Peter Ganz; David M Briscoe
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Targeted immunosuppression: no longer naïve.

Authors:  Robert S Hagan; Jonathan D Powell
Journal:  Clin Immunol       Date:  2011-10-25       Impact factor: 3.969

3.  Syk mediates BCR- and CD40-signaling integration during B cell activation.

Authors:  Haiyan Ying; Zhenping Li; Lifen Yang; Jian Zhang
Journal:  Immunobiology       Date:  2010-10-07       Impact factor: 3.144

Review 4.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

Review 5.  Primary antibody deficiencies.

Authors:  Anne Durandy; Sven Kracker; Alain Fischer
Journal:  Nat Rev Immunol       Date:  2013-06-14       Impact factor: 53.106

6.  Role for Akt3/protein kinase Bgamma in attainment of normal brain size.

Authors:  Rachael M Easton; Han Cho; Kristin Roovers; Diana W Shineman; Moshe Mizrahi; Mark S Forman; Virginia M-Y Lee; Matthias Szabolcs; Ron de Jong; Tilman Oltersdorf; Thomas Ludwig; Argiris Efstratiadis; Morris J Birnbaum
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  The CD8+ memory T-cell state of readiness is actively maintained and reversible.

Authors:  Atef Allam; Dietrich B Conze; Maria Letizia Giardino Torchia; Ivana Munitic; Hideo Yagita; Ryan T Sowell; Amanda L Marzo; Jonathan D Ashwell
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

8.  Naïve and memory B cells exhibit distinct biochemical responses following BCR engagement.

Authors:  Leen Moens; Alisa Kane; Stuart G Tangye
Journal:  Immunol Cell Biol       Date:  2016-04-22       Impact factor: 5.126

9.  ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus.

Authors:  Jared M Odegard; Leah D DiPlacido; Lark Greenwald; Michael Kashgarian; Dwight H Kono; Chen Dong; Richard A Flavell; Joe Craft
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Authors:  Xiao-Song Zhong; Maiko Matsushita; Jason Plotkin; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.